Skip to Main Content

Paper Details

Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.
Cells
9
2022
CTLs, Cancer, GVHD, allogeneic, cancer, cytotoxic T cells, donor lymphocyte, graft versus host disease, graft versus leukemia, hematopoietic stem cell, iPSC, iPSCs, induced pluripotent stem cells, recipient cells, rejuvenated CTLs, viral infections, virus, virus infected cells
Author NameAffiliation
Hiromitsu NakauchiThe Institute of Medical Science, The University of Tokyo
Hiromitsu NakauchiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Hiromitsu NakauchiThe Institute of Medical Science, The University of Tokyo
Hiromitsu NakauchiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
  • 1 - 4

Datasets

Release 1.2